Vivacelle Bio

Vivacelle Bio, founded as a clinical stage biotechnology company, focuses on developing innovative phospholipid nanoparticle products. Their core mission is to revolutionize circulatory support and septic shock treatment. The company's flagship product, VBI-1, is a colloid non-blood volume expander designed to treat hypovolemia more effectively than current standards. Their second product, VBI-S, aims to elevate blood pressure in septic shock patients. Vivacelle Bio targets the medical and healthcare markets, particularly in critical care settings.

Notable affiliated individuals include researchers and clinicians contributing to their product development and clinical trials. Key investors are often from the biotech and healthcare sectors, supporting the company's innovative approach. Vivacelle Bio has achieved significant milestones, including promising results from animal studies and a phase 2 clinical trial published in The Lancet Journal. Their impact lies in potentially transforming emergency treatments for hypovolemia and septic shock, offering safer and more effective alternatives to existing therapies.